- Home
- SGMT vs LPRO Comparison
SGMT vs LPRO Comparison
Compare SGMT & LPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMT
- LPRO
- Stock Information
- Founded
- SGMT 2006
- LPRO 2000
- Country
- SGMT United States
- LPRO United States
- Employees
- SGMT N/A
- LPRO N/A
- Industry
- SGMT
- LPRO Finance: Consumer Services
- Sector
- SGMT
- LPRO Finance
- Exchange
- SGMT Nasdaq
- LPRO Nasdaq
- Market Cap
- SGMT 238.7M
- LPRO 252.9M
- IPO Year
- SGMT 2023
- LPRO N/A
- Fundamental
- Price
- SGMT $8.30
- LPRO $1.83
- Analyst Decision
- SGMT Strong Buy
- LPRO Buy
- Analyst Count
- SGMT 8
- LPRO 6
- Target Price
- SGMT $26.88
- LPRO $3.00
- AVG Volume (30 Days)
- SGMT 651.1K
- LPRO 693.2K
- Earning Date
- SGMT 11-13-2025
- LPRO 11-06-2025
- Dividend Yield
- SGMT N/A
- LPRO N/A
- EPS Growth
- SGMT N/A
- LPRO N/A
- EPS
- SGMT N/A
- LPRO N/A
- Revenue
- SGMT N/A
- LPRO $16,254,999.00
- Revenue This Year
- SGMT N/A
- LPRO $306.78
- Revenue Next Year
- SGMT N/A
- LPRO $11.69
- P/E Ratio
- SGMT N/A
- LPRO N/A
- Revenue Growth
- SGMT N/A
- LPRO N/A
- 52 Week Low
- SGMT $1.73
- LPRO $0.70
- 52 Week High
- SGMT $11.41
- LPRO $6.92
- Technical
- Relative Strength Index (RSI)
- SGMT 54.70
- LPRO 42.79
- Support Level
- SGMT $8.02
- LPRO $1.78
- Resistance Level
- SGMT $9.46
- LPRO $1.95
- Average True Range (ATR)
- SGMT 0.62
- LPRO 0.12
- MACD
- SGMT 0.07
- LPRO -0.00
- Stochastic Oscillator
- SGMT 45.67
- LPRO 27.78
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About LPRO Open Lending Corporation
Open Lending Corp is engaged in providing automated lending services to financial institutions. The company offers loan analytics, risk-based pricing, risk modeling, and automated decision technology. Its Lenders Protection Program ("LPP") enables automotive lenders to make loans that are largely insured against, losses from defaults.